BioTelemetry Inc. (NASDAQ:BEAT) shares reached a new 52-week high on Tuesday . The stock traded as high as $19.24 and last traded at $18.80, with a volume of 959,065 shares trading hands. The stock had previously closed at $17.34.

Separately, Zacks Investment Research lowered BioTelemetry from a “strong-buy” rating to a “hold” rating in a research report on Tuesday.

The company has a market capitalization of $533.33 million and a P/E ratio of 48.41. The stock has a 50 day moving average of $16.76 and a 200-day moving average of $13.65.

BioTelemetry (NASDAQ:BEAT) last posted its earnings results on Tuesday, April 26th. The company reported $0.20 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.10 by $0.10. The business had revenue of $48.60 million for the quarter, compared to the consensus estimate of $46.54 million. The business’s revenue was up 12.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.06 earnings per share. Analysts expect that BioTelemetry Inc. will post $0.71 earnings per share for the current year.

A number of hedge funds and institutional investors have bought and sold shares of the company. Gabelli Funds LLC acquired a new position in BioTelemetry during the fourth quarter valued at $1,190,000. Russell Frank Co raised its position in BioTelemetry by 58.9% in the fourth quarter. Russell Frank Co now owns 249,457 shares of the company’s stock valued at $2,933,000 after buying an additional 92,455 shares in the last quarter. 1492 Capital Management LLC raised its position in BioTelemetry by 11.4% in the fourth quarter. 1492 Capital Management LLC now owns 321,761 shares of the company’s stock valued at $3,758,000 after buying an additional 32,932 shares in the last quarter. Royce & Associates LLC raised its position in BioTelemetry by 102.2% in the fourth quarter. Royce & Associates LLC now owns 606,700 shares of the company’s stock valued at $7,086,000 after buying an additional 306,700 shares in the last quarter. Finally, Wells Fargo & Company MN raised its position in BioTelemetry by 13.6% in the fourth quarter. Wells Fargo & Company MN now owns 994,163 shares of the company’s stock valued at $11,612,000 after buying an additional 119,328 shares in the last quarter.

BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.